Revenue ($USD) : $509,338,000
R&D spend : $223,062,000
Employees : 1,453
Fiscal year end : 12/31/2023
CEO : Asaf Danziger

www.novocure.com

Novocure specializes in developing therapies for difficult-to-treat tumors. The oncology company's wearable tumor treating fields (TTFields) technology is FDA-approved for glioblastoma and mesothelioma. Novocure is studying brain and pancreatic cancer and plans to launch its next indication in non-small cell lung cancer. An ovarian cancer trial failed in 2023, but the company said it still yielded encouraging findings. Novocure has its U.S. headquarters in Portsmouth, New Hampshire and R&D operations in Haifa, Israel. –JH